Determination of rearrangements in ALK gene in patients with non-small cell lung cancer (NSCLC), proposed as a mandatory procedure in most current international guidelines for the diagnosis and treatment of cancer. The aim of the study was to conduct a test by fluorescent hybridization in situ (FISH) of translocations involving ALK gene in patients referred for testing for EGFR gene mutations in the framework of the Society of oncologists-chemotherapeutists "Improvement of molecular genetic diagnosis in order to improve the efficiency of anticancer treatment» www.cancergenome.ru. Successful tests conducted in 189 out of 200 patients with NSCLC without mutations EGFR. There 12 positive tests (6.3%). The dependence of the frequency of detection of gene rearrangements of the ALK histological forms of cancer, smoking status and age of the patient was shown. The efficiency of wide FISH testing for ALK gene rearrangements in patients with glandular histological types of NSCLC was confirmed.

The aim was to identify cytogenetic disorders, proliferative activity and apoptosis in cells exfoliated buccal and nasal epithelium in patients with gastric cancer. The study involved 10 patients with an established diagnosis. The control group included 30 healthy people. It has been revealed that all this parameters were increased in buccal and nasal epithelium in patients with gastric cancer than in healthy people. The detected changes are systemic in nature and reflect the overall condition of the body. Moreover, we show reduction of karyological parameters after radical treatment, which indicates their prognostic significance.

In the article are described literary given about the frequency, the mechanisms, the factors of the risk of hemotherapy-induced liver injury with conducting of antitumorigenic medicinal therapy for patients with different oncologic diseases. Is represented the substantiation and the clinical experience, which makes it possible to make a conclusion about the high efficiency of the use of ademethionin (Heptral) for overcoming this complication of polychemotherapy. Are represented the results of their own three-stage study, which make it possible to make a conclusion about the high frequency of hemotherapy-induced liver injury with conducting of polychemotherapy, the analysis of the significance of the number of the factors of the risk is carried out. It is proven that the accompanying therapy by ademethionin (Heptral) in the patients with the metastatic forms of cancer with the factors of risk of hemotherapy-induced liver injury contributes to the retention of the level of the syndromes of cholestasis and cytolysis at the levels, which make it possible in the majority of patients to continue the conducted treatment regimen of polychemotherapy.

During the past 10 years, neoadjuvant chemotherapy has taken its rightful place in the treatment of breast cancer (BC). Clinical studies have shown that women who have achieved a complete pathologic tumor regression (pCR), are characterized by a significant improvement in survival compared with those who have not achieved such marked regression. A meta-analysis carried out on the instructions of FDA (Food and Drug Administration), has shown that the achievement of a complete pathologic response (pCR) as an intermediate marker of survival benefit, seen mainly in women with aggressive breast cancer subtypes: triple negative and HER2-positive breast cancer. In patients with HER2 + breast cancer, addition of trastuzumab to neoadjuvant chemotherapy doubles the frequency of pCR and correlates with increased survival.

The results of the first national experience of skin toxicity correction in patients with metastatic colorectal cancer (mCRC) receiving EGRF-inhibitors shown on the example of using of Panitumumab. The collection and evaluation of the data were produced in the framework of the project of the working group on maintenance therapy of Russian society of clinical oncologists and chemotherapeutists (RUSSCO) to develop recommendations for the prevention and treatment of dermatological toxicity in patients receiving EGFR-inhibitors. The project involved 10 centers in Russia.  In 58 patients receiving Panitumumab, the efficacy of prophylactic medication and symptomatic treatment of clinical manifestations of dermatological toxicity using available remedies was evaluated. The results confirm the effectiveness of preventive therapy. Optimal correction schemes of various manifestations of dermal toxicity were developed depending on the clinical manifestations and severity.

Prostate cancer is the most common form of cancer in men in Western countries and in some countries is in second place in the list of leading causes of cancer death in men. About 300 000 new cases of prostate cancer registered annually in Europe. In the world this number rises to 670,000 new cases. Prostate cancer in Russia takes 4^th place after lung cancer, gastric cancer and non-melanoma skin tumors. . Prostate cancer took 1st place in the list of the increase of incidence in Russia during the period 1999-2009 (by 2.8 times). Prostate tumors account for 6.9% of all malign tumors in men. Mortality due to prostate cancer is 10.4 per 100 000 in male population.